PVCTOTCPharmaceutical PreparationsFiscal year ends December 31

PROVECTUS BIOPHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.05+0.00 (+0.39%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2011 to 2025

-1575.3%

-1615.8%

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	-45.5%	-30.2%	–	–

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	-246.9%	24.6%	88.6%
Return on assets	-187.5%	-646.4%	-637.5%
Current ratio	0.85	0.01	0.08
Interest coverage	–	-2.8×	-991.9×
Diluted shares	234M	393M	420M

Return on equity split into margin, efficiency and leverage

Net margin-1615.8%

Asset turnover0.39×

Equity multiplier-0.14×

Return on equity, FY202588.6%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-1615.8%	0.39×	-0.14×	88.6%
FY2024	-766.9%	0.50×	-0.18×	69.8%
FY2023	-556.2%	0.32×	-0.25×	44.9%
FY2022	-359.4%	0.36×	-0.53×	68.3%

Parsed from the XBRL in Provectus Biopharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-300 reverse split on Apr 11, 2002
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PVCT.

Revenue growth-45.5% · median -10.7%

Operating margin-1363.5% · median -3117.3%

Net margin-1413.0% · median -3100.5%

Advertisement
300 × 250